Joen-Rong Sheu

Prof. Dr. Joen-Rong Sheu

Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
TJThanasekaran Jayakumar
Thanasekaran Jayakumar
CHCheng-Ying Hsieh
Cheng-Ying Hsieh
LJLee Jie-Jen
Lee Jie-Jen
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
Andrographis paniculata(Burm. F) Nees, generally known as “king of bitters,” is an herbaceous plant in the family Acanthaceae. In China, India, Thailand, and Malaysia, this plant has been widely used for treating sore throat, flu, and upper respiratory tract infections. Andrographolide, a major bioactive chemical constituent of the plant, has shown anticancer potential in various investigations. Andrographolide and its derivatives have anti-inflammatory effects in experimental models asthma, stroke, and arthritis. In recent years, pharmaceutical chemists have synthesized numerous andrographolide derivatives, which exhibit essential pharmacological activities such as those that are anti-inflammatory, antibacterial, antitumor, antidiabetic, anti-HIV, antifeedant, and antiviral. However, what is noteworthy about this paper is summarizing the effects of andrographolide against cardiovascular disease, platelet activation, infertility, and NF-κB activation. Therefore, this paper is intended to provide evidence reported in relevant literature on qualitative research to assist scientists in isolating and characterizing bioactive compounds.

1 October 2007 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
Ming-Yi ShenMing-Yi Shen
Ming-Yi Shen
GHGeorge Hsiao
George Hsiao
CLChang L. Liu
Chang L. Liu
TFTsorng H. Fong
Tsorng H. Fong
KLKuang H. Lin
Kuang H. Lin
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
Summary: Resveratrol has been reported to have antiplatelet activity; however, the detailed mechanisms have not yet been resolved. This study aimed to systematically examine the detailed mechanisms of resveratrol in the prevention of platelet activation in vitro and in vivo. Resveratrol (0·05–0·25 μmol/l) showed stronger inhibition of platelet aggregation stimulated by collagen (1 μg/ml) than other agonists. Resveratrol (0·15 and 0·25 μmol/l) inhibited collagen‐induced platelet activation accompanied by [Ca+2]i mobilization, thromboxane A2 (TxA2) formation, phosphoinositide breakdown, and protein kinase C (PKC) activation. Resveratrol markedly increased levels of NO/cyclic guanosine monophosphate (GMP), and cyclic GMP‐induced vasodilator‐stimulated phosphoprotein phosphorylation. Resveratrol markedly inhibited p38 mitogen‐activated protein kinase (MAPK) but not Jun N‐terminal kinase or extracellular signal‐regulated kinase‐2 phosphorylation in washed platelets. Resveratrol‐reduced hydroxyl radical (OH−) formation in the electron spin resonance study. In an in vivo study, resveratrol (5 mg/kg) significantly prolonged platelet plug formation of mice. In conclusion, the main findings of this study suggest that the inhibitory effects of resveratrol possibly involve (i) inhibition of the p38 MAPK‐cytosolic phospholipase A2‐arachidonic acid‐TxA2‐[Ca+2]i cascade and (ii) activation of NO/cyclic GMP, resulting in inhibition of phospholipase C and/or PKC activation. Resveratrol is likely to exert significant protective effects in thromboembolic‐related disorders by inhibiting platelet aggregation.

19 June 2004 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
GHGeorge Hsiao
George Hsiao
PCPo-Hsiu Chou
Po-Hsiu Chou
Ming-Yi ShenMing-Yi Shen
Ming-Yi Shen
DCDuen-Suey Chou
Duen-Suey Chou

19 January 2009 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
YCYi Chang
Yi Chang
CHCheng-Ying Hsieh
Cheng-Ying Hsieh
ZPZi-Aa Peng
Zi-Aa Peng
TYTing-Lin Yen
Ting-Lin Yen
GHGeorge Hsiao
George Hsiao
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
Puerarin, a major isoflavonoid derived from the Chinese medical herb Radix puerariae (kudzu root), has been reported to be useful in the treatment of various cardiovascular diseases. In the present study, we examined the detailed mechanisms underlying the inhibitory effects of puerarin on inflammatory and apoptotic responses induced by middle cerebral artery occlusion (MCAO) in rats. Treatment of puerarin (25 and 50 mg/kg; intraperitoneally) 10 min before MCAO dose-dependently attenuated focal cerebral ischemia in rats. Administration of puerarin at 50 mg/kg, showed marked reduction in infarct size compared with that of control rats. MCAO-induced focal cerebral ischemia was associated with increases in hypoxia-inducible factor-1α (HIF-1α), inducible nitric oxide synthase (iNOS), and active caspase-3 protein expressions as well as the mRNA expression of tumor necrosis factor-α (TNF-α) in ischemic regions. These expressions were markedly inhibited by the treatment of puerarin (50 mg/kg). In addition, puerarin (10~50 μM) concentration-dependently inhibited respiratory bursts in human neutrophils stimulated by formyl-Met-Leu-Phe. On the other hand, puerarin (20~500 μM) did not significantly inhibit the thiobarbituric acid-reactive substance reaction in rat brain homogenates. An electron spin resonance (ESR) method was conducted on the scavenging activity of puerarin on the free radicals formed. Puerarin (200 and 500 μM) did not reduce the ESR signal intensity of hydroxyl radical formation. In conclusion, we demonstrate that puerarin is a potent neuroprotective agent on MCAO-induced focal cerebral ischemia in vivo. This effect may be mediated, at least in part, by the inhibition of both HIF-1α and TNF-α activation, followed by the inhibition of inflammatory responses (i.e., iNOS expression), apoptosis formation (active caspase-3), and neutrophil activation, resulting in a reduction in the infarct volume in ischemia-reperfusion brain injury. Thus, puerarin treatment may represent a novel approach to lowering the risk of or improving function in ischemia-reperfusion brain injury-related disorders.

Verified
Journal Article
Open access
PDF file
CYChih-Hao Yang
Chih-Hao Yang
Ting-lin YenTing-lin Yen
Ting-lin Yen
CHChia-Yuan Hsu
Chia-Yuan Hsu
PTPhilip-Aloysius Thomas
Philip-Aloysius Thomas
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu
Jayakumar ThanasekaranJayakumar Thanasekaran
Jayakumar Thanasekaran
A key focus in the field of drug discovery has been motivated by the neuroprotection of natural compounds. Cerebral ischemia is a multifaceted pathological process with a series of mechanisms, and a perspective for the development of neuroprotectants from traditional herbal medicine or natural products is a promising treatment for this disease. Natural compounds with the effects of anti-oxidation, anti-inflammation, anti-apoptosis, and neurofunctional regulation exhibit therapeutic effects on experimental ischemic brain injury. Conferring to the pharmacological mechanisms underlying neuroprotection, a study found that androgapholide, a diterpene lactone compound, exhibits varying degrees of neuroprotective activities in both in vitro and in vivo experimental models of stroke. The neuroprotective mechanisms of andrographolide are suggested as: (I) increasing nuclear factor E2-related factor 2-heme oxygenase (Nrf2-HO-1) expression through p38-mitogen activated protein kinase (MAPK) regulation, (II) inducing cerebral endothelial cells (CEC) apoptosis and caspase-3 activation, (III) down regulating Bax, inducible nitric oxide synthase (iNOS), and (IV) inhibiting hydroxyl radical (OH−) formation, and activating transcription factor NF-κB signaling pathways. Recently, several researchers have also been trying to unveil the principal mechanisms involved in the neuroprotective effects of andrographolide. Therefore, this review aims to summarize an overview on the neuroprotective effects of andrographolide and exemplifies the essential mechanisms involved. This paper can provide information that andrographolide drug discovery may be a promising strategy for the development of a novel class of neuroprotective drug.

15 February 2012 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
TYTing-Lin Yen
Ting-Lin Yen
CHChung-King Hsu
Chung-King Hsu
WLWan-Jung Lu
Wan-Jung Lu
CHCheng-Ying Hsieh
Cheng-Ying Hsieh
GHGeorge Hsiao
George Hsiao
Joen-Rong SheuJoen-Rong Sheu
Joen-Rong Sheu